Cosciens BiopharmaCSCIF -5.24%62 Gross Margin % is 42.00% as of Mar. 2026, which is 19% below its 10-year median of 51.69. GuruFocus rates CSCIF with a GF Score™ of 62/100 and a GF Value™ of $2.35 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 738 Biotechnology companies, Cosciens Biopharma ranks worse than 70.6% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cosciens Biopharma had a gross margin of 42.00% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cosciens Biopharma Gross Margin % Related Terms
Cosciens Biopharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCIF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cosciens Biopharma (CSCIF) has a Gross Margin % of 42.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Cosciens Biopharma and its competitors. This is 19% below median its historical median of 51.69. Over the past decade, Cosciens Biopharma's Gross Margin % has ranged from 35.31 to 68.39. According to the industry distribution chart, Cosciens Biopharma ranks #521 out of 738 companies in the Biotechnology industry, placing it in the top 70.6%.
Is Cosciens Biopharma's Gross Margin % too high?
Cosciens Biopharma's current Gross Margin % of 42.00% is 19% below median its 10-year median of 51.69. Over the past 10 years, this metric has ranged from a low of 35.31 to a high of 68.39. The Biotechnology industry median Gross Margin % is 60.94. Cosciens Biopharma's value of 42.00% is 31.1% below this industry median. Based on the distribution chart, Cosciens Biopharma ranks #521 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cosciens Biopharma has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #521 out of 738 companies for Gross Margin %. This places Cosciens Biopharma in the lower half of its industry. The industry median Gross Margin % is 60.94. Cosciens Biopharma's value of 42.00% is 31.1% below this benchmark. Historically, Cosciens Biopharma's own Gross Margin % has ranged from 35.31 to 68.39 over the past decade. While the company's 10-year median is 51.69 vs. the industry median of 60.94, Cosciens Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosciens Biopharma's current Gross Margin % of 42.00% is 31.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cosciens Biopharma and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current Gross Margin % is 42.00%, which is 19% below median its own 10-year median of 51.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.35, compared to a current price of $1.99 — trading 15.3% below its estimated fair value. The current Gross Margin % is 42.00%, which is 19% below median its 10-year median of 51.69 and 31.1% below the Biotechnology industry median of 60.94. Cosciens Biopharma's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Gross Margin % is 42.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $1.99 is trading 15.3% below its estimated GF Value™ of $2.35.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
Gross Margin %: 42.00% (19% below median its 10-year median of 51.69)
GF Value™: $2.35 vs. price of $1.99 (15.3% below fair value)
Industry Position: 31.1% below the Biotechnology median (#521 of 738)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
62GF Score
Get the complete analysis for CSCIF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
